Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy by Goto, Yasuyuki et al.
Int. J. Med. Sci. 2007, 4 
 
1
International Journal of Medical Sciences 
ISSN 1449-1907 www.medsci.org 2007 4(1):1-6 
© Ivyspring International Publisher. All rights reserved 
Research Paper 
Grb2-associated binder 1 polymorphism was associated with the risk of 
Helicobactor pylori infection and gastric atrophy 
Yasuyuki Goto 1, Takafumi Ando 2, Kazuko Nishio 1, Sayo Kawai 1, Yoshiko Ishida 1, Mariko Naito 1, Hidemi 
Goto 2, Nobuyuki Hamajima 1  
1. Department of Preventive Medicine / Biostatistics and Medical Decision Making, Nagoya University Graduate School of 
Medicine, Nagoya 466-8550, Japan 
2. Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan   
Correspondence to: Yasuyuki Goto M.D., Ph.D., Department of Preventive Medicine / Biostatistics and Medical Decision Making, Nagoya 
University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550 Japan. Tel: +81-52-744-2133, Fax: 
+81-52-744-2971, e-mail: y-goto@med.nagoya-u.ac.jp 
Received: 2006.09.22; Accepted: 2006.10.25; Published: 2006.11.01 
Background: Various single nucleotide polymorphisms (SNPs) have explained the association between 
Helicobacter pylori (H. pylori) and gastric atrophy and cancer. This study investigated the associations of Grb2 
associated binder  1  (Gab1) polymorphism and the combination of PTPN11 gene encoding src homology 2 
domain-containing protein tyrosine phosphatase-2 (SHP2) and Gab1 gene with gastric cancer and gastric atrophy 
among H. pylori seropositive subjects.  
Methods: A single nucleotide polymorphism at intron 2 of Gab1 (JST164345) was examined for 454 Japanese 
health checkup examinees (126 males and 328 females) aged 35 to 85 without a history of gastric cancer and 202 
gastric cancer patients (134 males and 68 females) aged 33 to 94 with pathologically confirmed diagnosis of 
gastric adenocarcinoma.  
Results: The decreased OR of the Gab1 A/A for H. pylori seropositivity was 0.25 (95% confidence interval (CI): 
0.08-0.71). Among seropositive healthy controls, the OR of the Gab1 G/A+A/A for gastric atrophy was 
significant (OR=1.95, 95% CI: 1.12 -3.40). Seropositive individuals with PTPN11 G/G and Gab1 G/A+A/A 
demonstrated the highest risk of gastric atrophy with significance (OR=3.49, 95% CI: 1.54-7.90) relative to 
PTPN11  G/A+A/A  and Gab1 G/G, the lowest risk combination, as a reference. However, the gene-gene 
interaction between PTPN11 and Gab1 was not observed (OR=1.39, 95% CI: 0.41-4.66). Compared to gastric cancer 
case, the Gab1 did not influence the step of atrophy/metaplasia-gastric cancer sequence.  
Conclusions: This study represents that the Gab1 polymorphism was associated with the low risk of H. pylori 
infection and the high risk of gastric atrophy among seropositive healthy controls, and that seropositive 
individuals with PTPN11 G/G and Gab1 G/A+G/G were associated with the greatest risk of gastric atrophy. 
These findings require confirmation in much larger studies. 
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1.  Introduction 
Gastric cancer is the fourth most frequent cancer 
in the world, accounting for a large proportion of 
cancer cases in East Asia (China, Japan), Eastern 
Europe, and parts of Central and South America and it 
is the second most common cause of death from cancer 
[1].  Helicobacter pylori ( H. pylori) strains carrying the 
cytotoxin-associated gene A (cagA) gene are strongly 
associated with increased risk of gastric 
adenocarcinoma [2]. However, only some of those 
infected developed H. pylori-related disease such as 
g a s t r i c  u l c e r ,  a t r o p h y ,  c a n c e r  a n d  s o  o n .  I n  A s i a n  
countries such as Japan with high prevalence of 
cagA-positive  H. pylori infection, bacterial virulence 
factor has limitation of determining H. pylori-related 
disease. Therefore, we think it important to determine 
any host genetic predisposition to different outcome 
after the bacteria infection. 
H. pylori, especially cagA positive strains, plays a 
crucial role in the development of gastric atrophy and 
cancer [2,3]. CagA/ src homology 2 domain-containing 
protein tyrosine phosphatase-2 (SHP-2) interaction 
elicits cellular changes that increase the risk of 
carcinogenesis via extracellular-regulated protein 
kinase (ERK) activity [4,5]. CagA is regarded as a 
bacterial protein that mimics mammalian 
docking/scaffolding molecule such as Grb2-associated 
binder 1 (Gab1) [6].  
Gab1 consists of a pleckstrin homology domain, 
followed by a proline-rich region and multiple 
tyrosine phosphorylation sites that serve as binding 
sites for the SH2 domains of PI3-kinase, phospholipase 
Cγ, SHP2, and CrkL [7,8]. Gab1 functions upstream of 
Ras/mitogen-activated proten kinase (MAPK) 
signaling pathway, most likely to regulate the activity 
of the GDP / GTP exchanger, in a variety of growth Int. J. Med. Sci. 2007, 4 
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receptor signaling to activate ERK. SHP-2 is a 
ubiquitously expressed protein tyrosine phosphatase 
(PTPase) that contains two SH2 domains and an active 
catalytic domain [9,10]. SHP-2 PTPase activity is 
required for activation of the ERK subfamily of MAPK 
by epidermal growth factor (EGF) [11,12]. The 
previous reports suggest that the interaction between 
Gab1 and SHP2 is an essential component for ERK 
activation [13-17]. The activated SHP-2 is associated 
with Gab1 to mediate EGF-stimulated ERK2 activation, 
and Gab1 is the SHP-2 activator for the ERK MAP 
kinase pathway in EGF-stimulated cells [17].   
We have reported previously that G/G of the 
PTPN11 gene encoding SHP-2 increased the risk of 
gastric atrophy among the seropositive subjects [18]. 
The present study examined the association of a 
polymorphism of Gab1 with gastric cancer and gastric 
atrophy identified as the precursor lesion of 
gastric  cancer amongr the same Japanese subjects. 
There have been several SNPs identified in Gab1 gene 
in the Japan Single Nucleotide Polymorphisms (JSNP) 
database (http://snp.ims.u-tokyo.ac.jp). A 
particularly prevalent SNP is reported in intron 2 
(G/A), identified as JST164345 in JSNP database. The 
gene-gene interaction between PTPN11 and Gab1 was 
also evaluated.   
2.  Materials and methods 
Patients  
The clinical characteristics of the subjects were 
described in our previous paper [18]. Briefly, the 
control group was 454 health checkup examinees 
(HCE) without a history of cancer (126 males and 328 
females) aged 35 to 85, who attended a health checkup 
program supported by the Nagoya municipal 
government, in August and September 2000. The 
study protocol was approved by the Ethics Committee 
of the Aichi Cancer Center, with which the chief 
investigation (N.H.) was affiliated at the enrollment of 
study subjects. The case group was 202 patients (134 
males and 68 females) aged 33 to 94 with 
pathologically confirmed diagnosis of gastric 
adenocarcinoma, who underwent tumor resection in 
different affiliated hospitals of Nagoya University 
between January 1998 and June 2000. Informed 
consent was obtained from all the subjects. This study 
protocol was approved by the Ethics Committee of the 
Nagoya University Graduate School of Medicine. 
Tests for Helicobacer pylori (H. pylori) antibody and 
pepsinogens  
Anti-H. pylori IgG antibody tests, high-molecular- 
weight campylobacter-associated-protein (HM-CAP) 
ELISA (Enteric Products Inc., Westbury, NY) and 
HM-CAP with antigens extracted from clinically 
isolated Japanese H. pylori strains (J-HM-CAP) ELISA 
(Kyowa Medex, Tokyo, Japan), were used for the 
identification of H. pylori-infected participants (in the 
control group the former was used and in the case 
group both were used.). An ELISA value of 2.3 or over 
was regarded as positive for both tests. The infection 
was confirmed in all gastric cancer cases by culture 
and bacteriological tests (Gram-negative, oxidase, 
catalase, and urease test–positive spiral, curved rods) 
using biopsy specimens before gastric resection. 
Pepsinogens I and II (PG I and PG II) in serum were 
measured by radioimmunoassay using a 
commercially available kit (DINABOT, Tokyo, Japan). 
Gastric atrophy was defined as PG I< 70 ng/ml and 
PG I/PG II ratio <3.   
Genotype Assessment  
DNA was extracted from buffy coat fraction by 
Qiagen QIAamp DNA Blood Mini Kit (QIAGEN 
Inc.,Valencia,CA). A single nucleotide polymorphism 
(SNP) at intron 2 of Gab1, named as JST164345 in a 
database of Japan Single Nucleotide Polymorphisms 
(JSNP) at http://snp.ims.u-tokyo.ac.jp, was 
genotyped by PCR-CTPP (polymerase chain reaction 
with confronting two-pair primers) [19]. The primers 
were F1: 5’ GGT TTA AAC TTT ATT CTG ACT GTT 
CCC, R1: 5’ ACA CAA TTT AGT AAT AGC CAA 
AGT CAA C, F2: 5’ GTT GTT GTG AAG TAG AAA 
CTG ATT TCT AA, and R2: 5’ CTG GGG AGT GGG 
CCA. Genomic DNA was applied in a volume of 25 ul 
w i t h  0 . 1 2  m M  d N T P s ,  2 5  p m o l  o f  e a c h  p r i m e r ,  0 . 5  
units of AmpliTaq Gold (Perkin-Elmer Corp., Foster 
City, CA), and 2.5 ul 10xPCR buffer including 15mM 
MgCl2. The PCR was performed with initial 
denaturation at 95 ℃ for 10 minutes, followed by 
30cycles of denaturation at 95 ℃  for 1 minute, 
annealing at 63.5 ℃ for 1 minute and extension at 72
℃  for 5 minutes. The final extension was at 72  ℃ for 
5 minutes. Figure 1 shows the results of PCR-CTPP for 
Gab1. PCR product was visualized on a 2% agarose gel 
with ethidium bromide staining. A SNP of PTPN11 
that encodes SHP-2 (JST057927) was genotyped as 
reported in our previous report [19]. 
Figure 1 2% agarose gel showing the different genotypes for the Gab1 polymorphism. 
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Statistical analysis 
To prevent confounding bias, odds ratios (ORs) 
adjusted for sex and age with 95% confidence 
intervals (CIs) were calculated using logistic 
regression analysis.   
The Hardy- Weinberg equilibrium was examined 
for discrepancy between genotype and allele 
distributions using a χ² test. 
The product variable between gene and gene was 
included in the logistic model to evaluate the 
multiplicative interactive effect of genes. All tests were 
2-tailed with statistical significance setting at the level 
of p<0.05. Hardy-Weinberg equilibrium was tested for 
the Gab1 polymorphism. These calculations were 
performed by computer program STATA Version 8 
(STATA Corp, College Station, TX). 
3.  Results 
Study characteristics 
Although these summary has been described 
previously [18], it is shown here again for the readers’ 
convenience (Table 1). The prevalence of H. pylori 
seropositivity was significantly higher in the gastric 
cancer cases than in the healthy controls (100% vs. 
55.1%, p<0.001). One hundred seventy-nine of the 202 
(89%) gastric cancer cases had atrophy with 
significantly higher prevalence than the control group 
(35%). Atrophy was present in 54.8% of the 250 H. 
pylori seropositive healthy controls, which was 
significantly lower than the seropositive gastric cancer 
cases (p=0.001) but significantly higher than the 
seronegative healthy controls in which atrophy was 
present in only 10% of subjects (p<0.001). 
Table 1 Characteristics of the study subjects by source of 
recruitment. 
  Cases 
n(%) 
Controls 
n(%) 
Number of subjects  202   454 
Age in years 
(mean±standard 
deviation) 
66.7±12.3 58.4±11.9   
Sex    
Male  134 (66.3)  126 (27.8) 
Female  68 (33.7)  328 (72.3) 
H. pylori antibody     
Negative   0 (0)  204 (44.9) 
Positive   202 (100)  250 (55.1) 
Gastric atrophy     
Negative  23 (11.4)  296 (65.2) 
Positive   179 (88.6)  158 (34.8) 
Gab1 polymophism and H. pylori infection risk 
The  Gab1 genotype distribution of the control 
group was in the Hardy-Weinberg equilibrium 
(χ²=2.50, P=0.11). Table 2 shows that the genotype 
frequency and odds ratio (OR) of H. pylori 
seropositivity in healthy controls. The seropositivity 
rate for those with A/A was lowest. The decreased 
OR of A/A for H. pylori seropositivity was 0.25 (95% 
CI: 0.08-0.71). Twenty-one of the 204 seronegative 
healthy controls (10%) had atrophy, which were 
considered as the loss of H. pylori infection following 
sever atrophy. To ascertain whether the reduced 
infection risk related to this polymorphism follows 
sever atrophy, we arranged category so as to classify 
21 seronegative controls with atrophy as seropositive 
controls. We calculated the OR for H. pylori again and 
the corresponding OR was also a decreased risk with 
significance (OR=0.25, 95% CI: 0.09-0.71). 
Table 2 Genotype frequency and odds ratios (ORs) and 95% 
confidence intervals (95%CIs) of H. pylori Seropositivity 
(HP+) in Healthy Checkup Examinees. 
Genotype n  HP+ (%)  ORa(95%CI) 
G/G  317  171 (53.9)  1.00 (Reference) 
G/A  119  74 (62.2)  1.30 (0.81-2.07) 
A/A  18  5 (27.8)  0.25 (0.08-0.71) 
G/A+A/A  137  79 (57.7)  1.02 (0.67-1.56) 
aSex-age-adjusted odds ratio 
The combination of Gab1 and PTPN11and H. 
pylori-related gastric atrophy 
We have got subjects narrowed down to H. pylori 
seropositive healthy controls because of our interest in 
the association between these polymorphisms and 
digestive disease caused by H. pylori infection. We 
have reported previously that G/G of the PTPN11 gene 
encoding SHP-2 increased the risk of gastric atrophy 
[18]. Table 3 shows the age-sex-adjusted ORs of the 
Gab1 and the combinations of PTPN11  and Gab1 
genotypes for gastric atrophy among seropositive 
healthy controls. The OR of G/A+A/A for gastric 
atrophy was significant (OR=1.95, 95% CI 1.12 -3.40). 
Seropositive individuals with  the  PTPN11  G/G  and 
Gab1  G/A+A/A  demonstrated the highest risk of 
gastric atrophy with significance relative to PTPN11 
G/A+A/A and Gab1  G/G, the lowest risk 
combination, as a reference. However, the gene-gene 
interaction between the PTPN11and the Gab1 was not 
observed (OR=1.39, 95% CI 0.41-4.66). 
Table 3 ORs and 95% CIs for gastric atrophy (GA) of Gab1 
and the combinations of PTPN11  and  Gab1  genotypes 
among seropositive healthy controls. 
Genotype n  GA  (%)  ORa(95%CI) 
Gab1      
G/G  171  85 (49.7)  1.00 (Reference) 
G/A  74  48 (64.9)  1.87 (1.06-3.29) 
A/A  5  4 (80.0)  4.24 (0.45-39.7) 
G/A+A/A  79  52 (65.8)  1.95 (1.12-3.40) 
Total  250  137 (54.8)  
PTPN11b  Gab1      
G/A+A/A  G/G  49  20 (40.8)  1.00 (Reference) 
G/A+A/A  G/A+A/A  23  12 (52.2)  1.57 (0.58-4.29) 
G/G  G/G  121  64 (52.9)  1.60 (0.82-3.15) 
G/G  G/A+A/A  55  39 (70.9)  3.49 (1.54-7.90) 
Total 248  135  (54.4)   
aSex-age-adjusted odds ratio 
bTwo subjects could not be genotyped for PTPN11 
Gab1 polymorphism and the step of 
atrophy/metaplasia-gastric cancer 
We assessed whether  the  Gab1 gene 
polymorphism was associated with the development 
of H. pylori-related gastric cancer. Table 4 shows the Int. J. Med. Sci. 2007, 4 
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genotype frequency and ORs of the Gab1 genotypes 
for gastric cancer among the seropositive subjects. The 
Gab1 gene was not associated with the risk of gastric 
cancer among the seropositive subjects. In order to 
find out if the Gab1 polymorphism influenced the step 
of atrophy/metaplasia-gastric cancer sequence, 
proposed as the Correa cascade [20], we made a 
comparison between cases and controls with 
seropositive atrophy. The ORs of the G/A and A/A 
for gastric cancer was 1.05 (95% CI 0.63-1.74) and 1.05 
(95% CI 0.27-4.07), respectively. 
Table 4 The Gab1 genotype frequency and ORs for gastric 
cancer among the seropositive subjects. 
 
Genotype Cases 
n 
Controls 
n 
ORa (95%CI) 
G/G 119  171 1.00  (Reference) 
G/A  75  74  1.35 (0.88- 2.07) 
A/A  8  5  1.53 (0.46- 5.10) 
G/A+A/A 83  79  1.36  (0.90-2.06) 
Total 202  250   
aSex-age-adjusted odds ratio 
4.  Discussion 
This epidemiologic finding that the Gab1 
polymorphism was associated with H. pylori 
seropositivity and gastric atrophy is plausible. 
However, the Gab1 polymorphism did not influence 
the development of gastric cancer. 
The  Gab1 A/A  decreased the risk of H. pylori 
seropositivity, whereas the  Gab1 G/A+A/A was 
associated with gastric atrophy risk. In order to find 
out if the Gab1 polymorphism relates to loss of H. 
pylori infection following severe atrophy, which has 
been reported [21], we classified 21 seronegative 
controls with atrophy, which might be eradicated 
naturally, as seropositive controls. If the decreased OR 
for H. pylori seropositivity under this condition is not 
significant, we could conclude that the Gab1 
polymorphism  is associated with severe atrophy 
which induces the chance of natural eradication of the 
bacteria. However, the OR of the A/A genotype for H. 
pylori seropositivity was 0.25 (95% CI 0.09-0.71). So, 
the Gab1 polymorphism was associated with the low 
risk of the infection independent on severe atrophy. 
Although the Gab1 polymorphism prevented H. pylori 
infection, it was associated with the risk of atrophy 
identified as the precursor lesion of gastric cancer but 
not severe atrophy which is a final stage of atrophic 
status and loses H. pylori infection. Gab1 plays 
important roles in the signal transduction of cytokines, 
growth factors, antigen receptors [22]. The association 
between the polymorphism of cytokine genes such as 
interleukin 1B [23,24] and tumor necrosis factor A [25,26] 
and H. pylori seropositivity have been reported. Gab1 
may affect the H. pylori infection through the level of 
cytokines which are advantageous to eradication of H. 
pylori.  
These results should be interpreted with caution. 
The question is whether these apparently H. 
pylori-negative subjects were indeed truly negative or 
they eventually led to loss of the infection due to sever 
gastric atrophy. Because, in our study, gastric atrophy 
and H. pylori infection were based on serological 
diagnosis and the diagnosis happened to be imperfect, 
we might not discriminate severe atrophy exactly and 
further biological studies with histological assessment 
are needed to confirm the association. The functional 
changes caused by Gab1 polymorphism are not known 
and may be linkage disequilibrium with another gene. 
These are deficiencies of this study but we hope that 
our epidemiological and biologically plausible 
observation would stimulate interest in the study of 
the molecular mechanisms of action of this 
polymorphism. Because these results were based on 
the low frequency of A/A, they might be inconsistent 
due to the random errors. Studies of a larger size are 
needed to confirm our finding. This study, however, 
had 80% power to detect an absolute difference in the 
frequency of G/A+A/A, given 44% in the case and 
56% in the control. 
The PTPN11 polymorphism was associated with 
gastric atrophy among seropositive subjects [18]. The 
two tyrosine residues (Tyr-627 and Tyr-659) in the 
carboxyl-terminal region of Gab1 are required for 
SHP-2 binding to Gab1 and for EGF-stimulated ERK 
activation, in which another study reported 
Gab1/SHP-2 interaction was independent of ERK 
activation [27]. Tyr-627 and Tyr-659 of Gab1 constitute 
a bisphosphoryl tyrosine-based activation motif 
(BTAM) that binds to and activates SHP-2 [17]. Two 
SH2 domaines of SHP-2, termed N-SH2 and C-SH2 
domaines, are arranged in tandem at the amino 
(N)-terminal portion. SHP-2 has a low basal PTPase 
activity that can be activated by deletion of N-SH2 or 
both SH2 domains or by specific phosphopeptides 
that bind to the SH2 domains. The tandem SH2 
domains bind to Tyr-627 and Tyr-659 simultaneously 
in a specific orientation, in which Tyr-627 binds to the 
N-SH2 domain and Tyr-659 binds to the C-SH2 
domain [17]. Experiments with Gab1 mutants which 
are unable to bind to SHP-2 indicate that the 
interaction between SHP-2 and Gab1 and the 
activation of SHP-2 are essential for ERK activation 
[28-30]. The Gab1 polymorphism may affect the 
interaction with SHP-2 through the mechanism such 
as BTAM after H pylori infection, resulting in 
influencing the abnormal proliferation and movement 
of gastric epithelial cells related to gastric atrophy via 
the activation of ERK.   
This study also showed that the gastric atrophy 
risk was highest for those who carry the PTPN11 G/G 
and Gab1 G/A+A/A among seropositive subjects 
without interaction between those genotypes. 
Considering the mechanism such as BTAM, the 
epidemiologic interaction was expected, but not 
observed.  
Among the seropositive subjects, the Gab1 
polymorphism was not associated with gastric cancer. 
When we made a comparison between cases and 
controls with seropositive a t r o p h y ,  t h e  O R s  o f  G / A  
and A/A for gastric cancer were also each 
insignificant. This result showed that this Int. J. Med. Sci. 2007, 4 
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polymorphism did not influence the step of 
atrophy/metaplasia-gastric cancer sequence. As 
discussed in our previous report [18], our all gastric 
cancer cases had evidence of H. pylori infection 
because of the earlier presentation or diagnosis of 
cancer. 
In summary, the Gab1 A/A was associated with 
the low risk of H. pylori infection while the G/A and 
A/A genotypes together may increase the risk for 
gastric atrophy. The biological mechanism of this 
polymorphism remains to be elucidated. In addition, 
individuals with the PTPN11 G/G  and Gab1 
G/A+A/A demonstrated the greatest risk of gastric 
atrophy with no interaction. Our data provided 
further evidence for host genetic factors in the 
susceptibility to H pylori infection and H. pylori-related 
gastric atrophy.  Further investigation of the 
association requires much larger studies, as well as 
confirmatory biological studies with histological 
assessment.  
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